Multi-Omics Analysis in Autoimmunity: Identification of MicroRNA Regulatory Networks and Cell-Type-Specific Dysregulations in Multiple Sclerosis and Type 1 Diabetes

Abstract

Autoimmune diseases (AIDs) arise from complex immune dysregulations involving multiple immune cell types, cytokines, and molecular mediators. Among these, microRNAs (miRNAs) have recently emerged as key regulators of leukocyte processes and are frequently dysregulated in AIDs. However, their role in disease pathophysiology remains poorly understood. In this study, we performed a comprehensive analysis of miRNA expression in three immune populations, namely, CD14⁺ monocytes, neutrophils, and CD8⁺ T cells, in multiple sclerosis (MS) and type 1 diabetes (T1D), two prototypical AIDs. Our results reveal distinct patterns of miRNA dysregulation in each cell type, with monocytes from T1D patients showing enhanced M1 polarization and supporting inflammatory vascular damage. On the other hand, CD8⁺ T cells from MS patients show profound alterations related to CD8⁺ T cell-fate commitment, apoptosis regulation, and migratory capacity. Notably, we identified miRNAs that regulate key transcription factors such as FOXP3, IRF4, and RORγt, potentially shaping T cell differentiation programs. Our results suggest that miRNA networks play a central role in orchestrating disease-specific dysregulation in AIDs. By elucidating these intricate regulatory mechanisms, our study provides a foundation for future therapeutic strategies targeting miRNAs in autoimmunity.

Keywords

autoimmunity / data integration / microRNAs / multi-omics / multiple sclerosis / Type 1 diabetes

References

[1] Y. Hasin, M. Seldin, and A. Lusis, “Multi-omics Approaches to Disease,” Genome Biology 18, no. 1 (2017): 83.

[2] Y. V. Sun and Y. J. Hu, “Chapter Three—Integrative Analysis of Multi-omics Data for Discovery and Functional Studies of Complex Human Diseases,” In: T Friedmann, JC Dunlap, SF Goodwin, eds. “Advances in Genetics” (Academic Press, 2016): 147–190.

[3] B. I. Yamout and R. Alroughani, “Multiple Sclerosis,” Seminars in Neurology 38, no. 02 (2018): 212–225.

[4] R. Klaver, H. E. De Vries, G. J. Schenk, and J. J. G. Geurts, “Grey Matter Damage in Multiple Sclerosis: A Pathology Perspective,” Prion 7, no. 1 (2013): 66–75.

[5] F. D. Lublin, S. C. Reingold, J. A. Cohen, et al., “Defining the Clinical Course of Multiple Sclerosis: The 2013 Revisions,” Neurology 83, no. 3 (2014): 278–286.

[6] S. Subramanian, F. Khan, and I. B. Hirsch, “New Advances in Type 1 Diabetes,” Bmj 384 (2024): e075681.

[7] T. Quattrin, L. D. Mastrandrea, and L. S. K. Walker, “Type 1 Diabetes,” The Lancet 401, no. 10394 (2023): 2149–2162.

[8] L. Zhang, H. Wu, M. Zhao, C. Chang, and Q. Lu, “Clinical Significance of miRNAs in Autoimmunity,” Journal of Autoimmunity 109 (2020): 102438.

[9] Y. Liang, H. F. Pan, and D. Q. Ye, “Tc17 Cells in Immunity and Systemic Autoimmunity,” International Reviews of Immunology 34, no. 4 (2015): 318–331.

[10] A. K. Marwaha, S. Q. Crome, C. Panagiotopoulos, et al., “Cutting Edge: Increased IL-17–Secreting T Cells in Children With New-Onset Type 1 Diabetes,” The Journal of Immunology 185, no. 7 (2010): 3814–3818.

[11] M. A. Honardoost, R. Naghavian, F. Ahmadinejad, A. Hosseini, and K. Ghaedi, “Integrative Computational mRNA–miRNA Interaction Analyses of the Autoimmune-deregulated miRNAs and Well-known Th17 Differentiation Regulators: An Attempt to Discover New Potential miRNAs Involved in Th17 Differentiation,” Gene 572, no. 2 (2015): 153–162.

[12] M. Zhang, J. F. Wu, W. J. Chen, et al., “MicroRNA-27a/b Regulates Cellular Cholesterol Efflux, Influx and Esterification/Hydrolysis in THP-1 Macrophages,” Atherosclerosis 234, no. 1 (2014): 54–64.

[13] V. Bazioti, A. M. La Rose, S. Maassen, et al., “T Cell Cholesterol Efflux Suppresses Apoptosis and Senescence and Increases Atherosclerosis in Middle Aged Mice,” Nature Communications 13, no. 1 (2022): 3799.

[14] A. D. Gromovsky, R. C. Schugar, A. L. Brown, et al., “Δ-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators,” Arteriosclerosis, Thrombosis, and Vascular Biology 38, no. 1 (2018): 218–231.

[15] Q. Gong, H. Li, J. Song, and C. Lin, “LncRNA LINC01569 Promotes M2 Macrophage Polarization to Accelerate Hypopharyngeal Carcinoma Progression Through the miR-193a-5p/FADS1 Signaling Axis,” Journal of Cancer 14, no. 9 (2023): 1673–1688.

[16] R. Zhang, S. Niu, Z. Rong, et al., “A Potential Target for Diabetic Vascular Damage: High Glucose-Induced Monocyte Extracellular Vesicles Impair Endothelial Cells by Delivering miR-142-5p,” Frontiers in Bioengineering and Biotechnology 10 (2022): 913791.

[17] D. Di Silvestre, S. Garavelli, C. Procaccini, et al., “CD4+ T-Cell Activation Prompts Suppressive Function by Extracellular Vesicle-Associated MicroRNAs,” Frontiers in Cell and Developmental Biology 9 (2021): 753884.

[18] E. Koscianska, V. Baev, K. Skreka, et al., “Prediction and Preliminary Validation of Oncogene Regulation by miRNAs,” BMC Molecular Biology 8, no. 1 (2007): 79.

[19] J. Chen, S. Cai, T. Gu, F. Song, Y. Xue, and D. Sun, “MiR-140-3p Impedes Gastric Cancer Progression and Metastasis by Regulating BCL2/BECN1-Mediated Autophagy,” OncoTargets and Therapy 14 (2021): 2879–2892.

[20] P. Qiao, J. Zhu, X. Lu, et al., “miR-140-3p Suppresses the Proliferation and Migration of Macrophages,” Genetics and Molecular Biology 45 (2022): e20210160.

[21] Z. Salehi, R. Doosti, M. Beheshti, E. Janzamin, M. A. Sahraian, and M. Izad, “Differential Frequency of CD8+ T Cell Subsets in Multiple Sclerosis Patients With Various Clinical Patterns,” PLoS ONE 11, no. 7 (2016): e0159565.

[22] J. Dong, W. J. Huth, N. Marcel, Z. Zhang, L. L. Lin, and L. F. Lu, “miR-15/16 Clusters Restrict Effector Treg Cell Differentiation and Function,” Journal of Experimental Medicine 220, no. 10 (2023): e20230321.

[23] G. Alvisi, J. Brummelman, S. Puccio, et al., “IRF4 instructs Effector Treg Differentiation and Immune Suppression in human Cancer,” The Journal of Clinical Investigation 130, no. 6 (2020): 3137–3150.

[24] Z. Lei, G. Xu, L. Wang, et al., “MiR-142-3p Represses TGF-β-induced Growth Inhibition Through Repression of TGFβR1 in Non-small Cell Lung Cancer,” The FASEB Journal 28, no. 6 (2014): 2696–2704.

[25] J. M. Moreau, M. Velegraki, C. Bolyard, M. D. Rosenblum, and Z. Li, “Transforming Growth Factor–β1 in Regulatory T Cell Biology,” Science Immunology 7, no. 69 (2022): eabi4613.

[26] Y. Peng, X. Deng, Q. Zeng, and Y. Tang, “Tc17 cells in Autoimmune Diseases,” Chinese Medical Journal 135, no. 18 (2022): 2167.

[27] C. Lückel, F. S. R. Picard, and M. Huber, “Tc17 biology and Function: Novel Concepts,” European Journal of Immunology 50, no. 9 (2020): 1257–1267.

[28] Y. Wu, A. Huang, T. Li, et al., “MiR-152 Reduces human Umbilical Vein Endothelial Cell Proliferation and Migration by Targeting ADAM17,” FEBS Letters 588, no. 12 (2014): 2063–2069.

[29] J. Y. Hsieh, T. S. Huang, S. M. Cheng, et al., “miR-146a-5p Circuitry Uncouples Cell Proliferation and Migration, but Not Differentiation, in human Mesenchymal Stem Cells,” Nucleic Acids Research 41, no. 21 (2013): 9753–9763.

[30] C. Evangelisti, M. C. Florian, I. Massimi, et al., “MiR-128 Up-regulation Inhibits Reelin and DCX Expression and Reduces Neuroblastoma Cell Motility and Invasiveness,” The FASEB Journal 23, no. 12 (2009): 4276–4287.

[31] A. Cimmino, G. A. Calin, M. Fabbri, et al., “miR-15 and miR-16 Induce Apoptosis by Targeting BCL2,” Proceedings of the National Academy of Sciences of the United States of America 102, no. 39 (2005): 13944–13949.

[32] L. Tan, L. Liu, J. Yao, and C. Piao, “miR-145-5p Attenuates Inflammatory Response and Apoptosis in Myocardial Ischemia-reperfusion Injury by Inhibiting (NADPH) Oxidase Homolog 1,” Experimental Animals 70, no. 3 (2021): 311–321.

[33] Y. Du, X. Ma, L. Ma, et al., “Inhibition of microRNA-148b-3p Alleviates Oxygen-glucose Deprivation/Reoxygenation-induced Apoptosis and Oxidative Stress in HT22 Hippocampal Neuron via Reinforcing Sestrin2/Nrf2 Signalling,” Clinical and Experimental Pharmacology & Physiology 47, no. 4 (2020): 561–570.

[34] H. Lin, J. Chu, D. Yuan, K. Wang, F. Chen, and X. Liu, “MiR-206 May Regulate Mitochondrial ROS Contribute to the Progression of Myocardial Infarction via TREM1,” BMC Cardiovascular Disorders 23, no. 1 (2023): 470.

[35] L. Wang, J. Xu, H. Liu, J. Li, and H. Hao, “PM2.5 inhibits SOD1 Expression by Up-regulating microRNA-206 and Promotes ROS Accumulation and Disease Progression in Asthmatic Mice,” International Immunopharmacology 76 (2019): 105871.

[36] L. Zhao, Y. Qi, L. Xu, et al., “MicroRNA-140-5p Aggravates Doxorubicin-induced Cardiotoxicity by Promoting Myocardial Oxidative Stress via Targeting Nrf2 and Sirt2,” Redox Biology 15 (2018): 284–296.

[37] Q. Q. Liu, K. Ren, S. H. Liu, W. M. Li, C. J. Huang, and X. H. Yang, “MicroRNA-140-5p Aggravates Hypertension and Oxidative Stress of Atherosclerosis via Targeting Nrf2 and Sirt2,” International Journal of Molecular Medicine 43, no. 2 (2019): 839–849.

[38] C. Chang, K. Huang, X. Xu, et al., “MiR-23a-5p Alleviates Chronic Obstructive Pulmonary Disease Through Targeted Regulation of RAGE-ROS Pathway,” Respiratory Research 25, no. 1 (2024): 93.

[39] W. C. Schrottmaier, O. V. Oskolkova, G. Schabbauer, and T. Afonyushkin, “MicroRNA miR-320a Modulates Induction of HO-1, GCLM and OKL38 by Oxidized Phospholipids in Endothelial Cells,” Atherosclerosis 235, no. 1 (2014): 1–8.

[40] H. Du, Z. Yin, Y. Zhao, et al., “miR-320a Induces Pancreatic β Cells Dysfunction in Diabetes by Inhibiting MafF,” Molecular Therapy—Nucleic Acids 26 (2021): 444–457.

[41] Y. Zhao, D. Dong, E. A. Reece, A. R. Wang, and P. Yang, “Oxidative Stress-induced miR-27a Targets the Redox Gene Nuclear Factor Erythroid 2-related Factor 2 in Diabetic Embryopathy,” American Journal of Obstetrics and Gynecology 218, no. 1 (2018): 136.e1–e10.

[42] Y. Guo, H. Zeng, and C. Gao, “The Role of Neutrophil Extracellular Traps in Central Nervous System Diseases and Prospects for Clinical Application,” Oxidative Medicine and Cellular Longevity 2021, no. 1 (2021): 9931742.

[43] A. Subramanian, P. Tamayo, V. K. Mootha, et al., “Gene Set Enrichment Analysis: A Knowledge-based Approach for Interpreting Genome-wide Expression Profiles,” Proceedings of the National Academy of Sciences 102, no. 43 (2005): 15545–15550.

[44] M. Ashburner, C. A. Ball, J. A. Blake, et al., “Gene Ontology: Tool for the Unification of Biology,” Nature Genetics 25, no. 1 (2000): 25–29.

[45] S. Cui, S. Yu, H. Y. Huang, et al., “miRTarBase 2025: Updates to the Collection of Experimentally Validated microRNA–target Interactions,” Nucleic Acids Research 53, no. D1 (2025): D147–D156.

[46] A. C. Hauschild, C. Pastrello, G. K. A. Ekaputeri, et al., “MirDIP 5.2: Tissue Context Annotation and Novel microRNA Curation,” Nucleic Acids Research 51, no. D1 (2023): D217–D225.

[47] X. Liu, S. N. Robinson, T. Setoyama, et al., “FOXP3 is a Direct Target of miR15a/16 in Umbilical Cord Blood Regulatory T Cells,” Bone Marrow Transplantation 49, no. 6 (2014): 793–799.

[48] M. M. Gonzalez, A. O. Bamidele, P. A. Svingen, et al., “BMI1 maintains the Treg Epigenomic Landscape to Prevent Inflammatory Bowel Disease,” The Journal of Clinical Investigation 131, no. 12 (2021): e140755.

[49] J. J. L. Jacobs, K. Kieboom, S. Marino, R. A. DePinho, and M. van Lohuizen, “The Oncogene and Polycomb-group Gene Bmi-1 Regulates Cell Proliferation and Senescence Through the ink4a Locus,” Nature 397, no. 6715 (1999): 164–168.

[50] S. Meng, M. Luo, H. Sun, et al., “Identification and Characterization of Bmi-1-responding Element Within the Human p16 Promoter*,” Journal of Biological Chemistry 285, no. 43 (2010): 33219–33229.

[51] A. Chaudhry, R. M. Samstein, P. Treuting, et al., “Interleukin-10 Signaling in Regulatory T Cells Is Required for Suppression of Th17 Cell-Mediated Inflammation,” Immunity 34, no. 4 (2011): 566–578.

[52] D. Aran, A. P. Looney, L. Liu, et al., “Reference-based Analysis of Lung Single-cell Sequencing Reveals a Transitional Profibrotic Macrophage,” Nature Immunology 20, no. 2 (2019): 163–172.

[53] B. Z. Chaudhry, J. A. Cohen, and D. S. Conway, “Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis,” Neurotherapeutics 14, no. 4 (2017): 859–873.

[54] G. F. Debes, C. N. Arnold, A. J. Young, et al., “Chemokine Receptor CCR7 Required for T Lymphocyte Exit From Peripheral Tissues,” Nature Immunology 6, no. 9 (2005): 889–894.

[55] J. G. Cyster, “Leukocyte Migration: Scent of the T Zone,” Current Biology 10, no. 1 (2000): R30–R33.

[56] T. Tian, Z. Liu, H. Chen, and Z. Cui, “S100A1 Promotes Cell Proliferation and Migration and Is Associated With Lymph Node Metastasis in Ovarian Cancer,” Discovery Medicine 23, no. 127 (2017): 235–245.

[57] P. Badia-i-Mompel, J. Vélez Santiago, and J. Braunger, “decoupleR: Ensemble of Computational Methods to Infer Biological Activities From Omics Data,” Bioinformatics Advances 2, no. 1 (2022): vbac016.

[58] M. Huber, S. Heink, H. Grothe, et al., “A Th17-Like Developmental Process Leads to CD8+ Tc17 Cells With Reduced Cytotoxic Activity,” European Journal of Immunology 39, no. 7 (2009): 1716–1725.

[59] S. Aibar, C. B. González-Blas, T. Moerman, et al., “SCENIC: Single-cell Regulatory Network Inference and Clustering,” Nature Methods 14, no. 11 (2017): 1083–1086.

[60] J. N. U. Yaochite, C. Caliari-Oliveira, M. R. Davanso, et al., “Dynamic Changes of the Th17/Tc17 and Regulatory T Cell Populations Interfere in the Experimental Autoimmune Diabetes Pathogenesis,” Immunobiology 218, no. 3 (2013): 338–352.

[61] K. J. Riley, G. S. Rabinowitz, T. A. Yario, J. M. Luna, R. B. Darnell, and J. A. Steitz, “EBV and human microRNAs co-target Oncogenic and Apoptotic Viral and human Genes During Latency,” The EMBO Journal 31, no. 9 (2012): 2207–2221.

[62] J. Mudter, J. Yu, C. Zufferey, et al., “IRF4 regulates IL-17A Promoter Activity and Controls RORγt-dependent Th17 Colitis in Vivo,” Inflammatory Bowel Diseases 17, no. 6 (2011): 1343–1358.

[63] M. Huber and M. Lohoff, “IRF4 at the Crossroads of Effector T-cell Fate Decision,” European Journal of Immunology 44, no. 7 (2014): 1886–1895.

[64] C. G. Lee, W. Hwang, K. E. Maeng, et al., “IRF4 regulates IL-10 Gene Expression in CD4+ T Cells Through Differential Nuclear Translocation,” Cellular Immunology 268, no. 2 (2011): 97–104.

[65] M. J. McGeachy and D. J. Cua, “Th17 Cell Differentiation: The Long and Winding Road,” Immunity 28, no. 4 (2008): 445–453.

[66] F. V. Karginov and G. J. Hannon, “Remodeling of Ago2–mRNA Interactions Upon Cellular Stress Reflects miRNA Complementarity and Correlates With Altered Translation Rates,” Genes & Development 27, no. 14 (2013): 1624–1632.

[67] S. Matis, A. Grazia Recchia, M. Colombo, et al., “MiR-146b-5p Regulates IL-23 Receptor Complex Expression in Chronic Lymphocytic Leukemia Cells,” Blood Advances 6, no. 20 (2022): 5593–5612.

[68] V. Niggli, “Insights Into the Mechanism for Dictating Polarity in Migrating T-cells,” International Review of Cell and Molecular Biology 312 (2014): 201–270.

[69] S. You, X. He, M. Wang, L. Mao, and L. Zhang, “Tanshinone IIA Suppresses Glioma Cell Proliferation, Migration and Invasion both in Vitro and in Vivo Partially through miR-16-5p/Talin-1 (TLN1) Axis,” Cancer Management and Research 12 (2020): 11309–11320.

[70] V. L. J. Tybulewicz and R. B. Henderson, “Rho family GTPases and Their Regulators in Lymphocytes,” Nature Reviews Immunology 9, no. 9 (2009): 630–644.

[71] R. C. Williamson, C. A. M. Cowell, C. L. Hammond, et al., “Coronin-1C and RCC2 Guide Mesenchymal Migration by Trafficking Rac1 and Controlling GEF Exposure,” Journal of Cell Science 127, no. 19 (2014): 4292–4307.

[72] L. Tebbi, B. Mansoori, S. Safaei, et al., “MiR-146a Restoration Suppresses Triple-Negative Breast Cancer Cell Migration: A Bioinformatic and in Vitro Study,” Advanced Pharmaceutical Bulletin 12, no. 4 (2022): 842–849.

[73] M. Stetler-Stevenson, A. Mansoor, M. Lim, et al., “Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Reactive and Neoplastic Lymphoid Cells,” Blood 89, no. 5 (1997): 1708–1715.

[74] S. Willimott and S. D. Wagner, “miR-125b and miR-155 Contribute to BCL2 Repression and Proliferation in Response to CD40 Ligand (CD154) in Human Leukemic B-cells*,” Journal of Biological Chemistry 287, no. 4 (2012): 2608–2617.

[75] C. Lückel, F. Picard, H. Raifer, et al., “IL-17+ CD8+ T Cell Suppression by Dimethyl Fumarate Associates With Clinical Response in Multiple Sclerosis | Nature Communications,” Nature Communications 10, no. 1 (2019): 5722.

[76] T. W. Houston, Q. Howlett-Prieto, C. Regenauer, et al., “Increased Percentage of CD8+CD28− Regulatory T Cells with Fingolimod Therapy in Multiple Sclerosis,” Neurology Neuroimmunology & Neuroinflammation 10, no. 2 (2023): e200075.

[77] G. Frisullo, V. Nociti, R. Iorio, et al., “CD8+Foxp3+ T Cells in Peripheral Blood of Relapsing-remitting Multiple Sclerosis Patients,” Human Immunology 71, no. 5 (2010): 437–441.

[78] S. Rajabi, K. Sadegi, S. Hajisobhani, M. Kaveh, and E. Taghizadeh, “miR-146a and miR-155 as Promising Biomarkers for Prognosis and Diagnosis of Multiple Sclerosis: Systematic Review,” Egyptian Journal of Medical Human Genetics 25, no. 1 (2024): 73.

[79] J. C. C. Lorenzi, D. G. Brum, D. L. Zanette, et al., “miR-15a and 16-1 Are Downregulated in CD4+ T Cells of Multiple Sclerosis Relapsing Patients,” International Journal of Neuroscience 122, no. 8 (2012): 466–471.

[80] M. Mostahfezian, Z. Azhir, F. Dehghanian, and Z. Hojati, “Expression Pattern of microRNAs, miR-21, miR-155 and miR-338 in Patients With Type 1 Diabetes,” Archives of Medical Research 50, no. 3 (2019): 79–85.

[81] M. Yang, L. Ye, B. Wang, et al., “Decreased miR-146 Expression in Peripheral Blood Mononuclear Cells Is Correlated With Ongoing Islet Autoimmunity in Type 1 Diabetes Patients 1型糖尿病患者外周血单个核细胞miR-146表达下调与胰岛持续免疫失衡相关,” Journal of Diabetes 7, no. 2 (2015): 158–165.

[82] A. Amoruso, M. Blonda, M. Gironi, et al., “Immune and central Nervous System-related miRNAs Expression Profiling in Monocytes of Multiple Sclerosis Patients,” Scientific Reports 10, no. 1 (2020): 6125.

[83] R. I. Aqeilan, G. A. Calin, and C. M. Croce, “miR-15a and miR-16-1 in Cancer: Discovery, Function and Future Perspectives,” Cell Death & Differentiation 17, no. 2 (2010): 215–220.

[84] J. Hu, S. Huang, X. Liu, Y. Zhang, S. Wei, and X. Hu, “miR-155: An Important Role in Inflammation Response,” Journal of Immunology Research 2022, no. 1 (2022): 7437281.

[85] A. A. Elkhodiry, D. A. Zamzam, and H. M. El Tayebi, “miR-155 and Functional Proteins of CD8+ T Cells as Potential Prognostic Biomarkers for Relapsing-remitting Multiple Sclerosis,” Multiple Sclerosis and Related Disorders 53 (2021): 103078.

[86] X. Liu, J. Li, F. Qin, and S. Dai, “miR-152 as a Tumor Suppressor microRNA: Target Recognition and Regulation in Cancer,” Oncology Letters 11, no. 6 (2016): 3911–3916.

[87] J. Martorell-Marugán, R. López-Domínguez, A. García-Moreno, et al., “A Comprehensive Database for Integrated Analysis of Omics Data in Autoimmune Diseases,” BMC Bioinformatics [Electronic Resource] 22, no. 1 (2021): 343.

[88] H. Zhang, Y. Zhou, B. Yu, et al., “Multi-Omics Approaches to Discover Biomarkers of Thyroid Eye Disease: A Systematic Review,” International Journal of Biological Sciences 20, no. 15 (2024): 6038–6055.

[89] W. Elison, L. Chang, Y. Xie, et al., “Single Cell Multiomics Reveals Drivers of Metabolic Dysfunction-associated Steatohepatitis [Preprint],” medRxiv (2025). 2025.05.09.25327043.

[90] R Core Team, R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing; 2021.

[91] B. S. Carvalho and R. A. Irizarry, “A Framework for Oligonucleotide Microarray Preprocessing,” Bioinformatics 26, no. 19 (2010): 2363–2367.

[92] A. Kauffmann, R. Gentleman, and W. Huber, “arrayQualityMetrics—a Bioconductor Package for Quality Assessment of Microarray Data,” Bioinformatics 25, no. 3 (2009): 415–416.

[93] D. de Rie, I. Abugessaisa, T. Alam, et al., “An Integrated Expression Atlas of miRNAs and Their Promoters in human and Mouse,” Nature Biotechnology 35, no. 9 (2017): 872–878.

[94] G. E. Hoffman and E. E. Schadt, “variancePartition: Interpreting Drivers of Variation in Complex Gene Expression Studies,” BMC Bioinformatics [Electronic Resource] 17, no. 1 (2016): 483.

[95] J. T. Leek, W. E. Johnson, H. S. Parker, A. E. Jaffe, and J. D. Storey, “The sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments,” Bioinformatics 28, no. 6 (2012): 882–883.

[96] M. E. Ritchie, B. Phipson, D. Wu, et al., “limma Powers Differential Expression Analyses for RNA-sequencing and Microarray Studies,” Nucleic Acids Research 43, no. 7 (2015): e47.

[97] J. D. Storey, “A Direct Approach to False Discovery Rates,” Journal of the Royal Statistical Society Series B: Statistical Methodology 64, no. 3 (2002): 479–498.

[98] J. Li, X. Han, Y. Wan, et al., “TAM 2.0: Tool for MicroRNA Set Analysis,” Nucleic Acids Research 46, no. W1 (2018): W180–W185.

[99] M. Soutschek, T. Germade, P. L. Germain, and G. Schratt, “enrichMiR Predicts Functionally Relevant microRNAs Based on Target Collections,” Nucleic Acids Research 50, no. W1 (2022): W280–W289.

[100] V. Agarwal, G. W. Bell, J. W. Nam, and D. P. Bartel, “Predicting Effective microRNA Target Sites in Mammalian mRNAs, Izaurralde E, Ed,” Elife 4 (2015): e05005.

[101] A. Kozomara, M. Birgaoanu, and S. Griffiths-Jones, “miRBase: From microRNA Sequences to Function,” Nucleic Acids Research 47, no. D1 (2019): D155–D162.

[102] A. Untergasser, I. Cutcutache, T. Koressaar, et al., “Primer3—new Capabilities and Interfaces,” Nucleic Acids Research 40, no. 15 (2012): e115.

[103] D. J. McCarthy, K. R. Campbell, A. T. L. Lun, and Q. F. Wills, “Scater: Pre-processing, Quality Control, Normalization and Visualization of Single-cell RNA-seq Data in R,” Bioinformatics 33, no. 8 (2017): 1179–1186.

[104] L. Haghverdi, A. T. L. Lun, M. D. Morgan, and J. C. Marioni, “Batch Effects in Single-cell RNA-sequencing Data Are Corrected by Matching Mutual Nearest Neighbors,” Nature Biotechnology 36, no. 5 (2018): 421–427.

[105] N. Novershtern, A. Subramanian, L. N. Lawton, et al., “Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis,” Cell 144, no. 2 (2011): 296–309.

[106] G. Monaco, B. Lee, W. Xu, et al., “RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types,” Cell Reports 26, no. 6 (2019): 1627–1640.e7.

[107] Y. Chen, L. Chen, A. T. L. Lun, P. L. Baldoni, and G. K. Smyth, “edgeR v4: Powerful Differential Analysis of Sequencing Data With Expanded Functionality and Improved Support for Small Counts and Larger Datasets,” Nucleic Acids Research 53, no. 2 (2025): gkaf018.

[108] S. Müller-Dott, E. Tsirvouli, M. Vazquez, et al., “Expanding the Coverage of Regulons From High-confidence Prior Knowledge for Accurate Estimation of Transcription Factor Activities,” Nucleic Acids Research 51, no. 20 (2023): 10934–10949.

[109] M. R. Tom, J. Li, A. Ueno, et al., “Novel CD8+ T-Cell Subsets Demonstrating Plasticity in Patients With Inflammatory Bowel Disease,” Inflammatory Bowel Diseases 22, no. 7 (2016): 1596–1608.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.